Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Prior Antibiotic Exposure May Hinder Checkpoint Inhibitor Efficacy

Key clinical point: Prior antibiotic exposure may hinder the efficacy of checkpoint inhibitors.

Major finding: Median overall survival was 2 months with prior antibiotic exposure versus 26 months without.

Study details: A prospective, observational study of 196 patients with various cancers treated with immune checkpoint inhibitors.

Disclosures: The study was internally supported. Dr. Pinato reported receiving grant funding from Merck and Bristol-Myers Squibb unrelated to the study, as well as honoraria from ViiV Healthcare.


Pinato DJ et al. ASCO-SITC, Abstract 147.